Trastuzumab was the first humanized monoclonal antibody approved by the Food and Drug Administration (FDA) of the USA in 1998 and two years later by the European Medicines Agency (EMA) for the treatment of both early stage and metastatic HER2 overexpressing breast cancer [13, 16, 17]. The gene discussed is ERBB2; the disease is breast cancer.